Compare OOMA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | ACIU |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.1M | 213.3M |
| IPO Year | 2015 | 2016 |
| Metric | OOMA | ACIU |
|---|---|---|
| Price | $11.59 | $3.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $19.00 | $10.00 |
| AVG Volume (30 Days) | 289.9K | ★ 1.4M |
| Earning Date | 12-08-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $264,115,000.00 | $5,482,957.00 |
| Revenue This Year | $6.45 | N/A |
| Revenue Next Year | $11.53 | $738.95 |
| P/E Ratio | $142.71 | ★ N/A |
| Revenue Growth | ★ 4.22 | N/A |
| 52 Week Low | $9.79 | $1.43 |
| 52 Week High | $15.65 | $4.00 |
| Indicator | OOMA | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 50.19 |
| Support Level | $10.50 | $2.87 |
| Resistance Level | $12.04 | $3.45 |
| Average True Range (ATR) | 0.63 | 0.31 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 47.83 | 38.09 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.